Wednesday, July 8, 2026

Drug profile · INN

indigotindisulfonate sodium

indigotindisulfonate sodium (BLUDIGO) is a diagnostic. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — indigotindisulfonate sodium
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
2
Data quality
0.84

Quick answer

indigotindisulfonate sodium (BLUDIGO) is a diagnostic. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN indigotindisulfonate sodium
Brand BLUDIGO
Mechanism Diagnostic
Route INTRAVENOUS
Formulation SOLUTION

Mechanism of action

Diagnostic

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Indigo naturalis ointment Phase 2 · Chinese Academy of · Psoriasis
  2. LAB4 Phase 2 · Cardiff Oncology · Graves' Disease

Frequently asked questions

What is indigotindisulfonate sodium?

indigotindisulfonate sodium (BLUDIGO) is a diagnostic. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for indigotindisulfonate sodium?

BLUDIGO is a marketed brand name for indigotindisulfonate sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of indigotindisulfonate sodium?

indigotindisulfonate sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.